Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined